Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06419946Phase 3Recruiting

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Role: collaborator

NCT07498959Not ApplicableRecruiting

Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Role: collaborator

NCT06273644Not ApplicableRecruiting

Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment

Role: collaborator

NCT07291141Recruiting

A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis

Role: collaborator

NCT06445621Recruiting

Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test

Role: collaborator

All 5 trials loaded